The Methodological Appendix describes the analytical framework for this pharmacovigilance study using spontaneous adverse event reports from the FDA Adverse Event Reporting System (FAERS).
王, 思文
core +1 more source
Supplementary table and figure for the manuscript titled, "Nemolizumab for treatment-refractory cutaneous adverse events in patients with cancer: A retrospective multi-institutional case series" in the Journal of the American Academy of ...
Karagenova, Ralina
core +1 more source
Successful use of nemolizumab for refractory pruritus in cutaneous T-cell lymphoma. [PDF]
JAAD Case RepLi C, Rogers J, Raef H, Aspey L.
europepmc +1 more source
Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis. [PDF]
Intractable Rare Dis ResTanaka H, Ishii T.
europepmc +1 more source
Novel intralesional nemolizumab for chronic scalp prurigo nodularis. [PDF]
JAAD Case RepGaven E, Siddiqui S, Stout M.
europepmc +1 more source
Dupilumab-Induced Vitiligo Managed Effectively With Nemolizumab and Targeted Topical Therapy. [PDF]
CureusColon J, Falabella A.
europepmc +1 more source
Nemolizumab for treatment of lichen amyloidosis
JAAD Case ReportsNakagawa, Seitaro +2 more
openaire +2 more sources
Treatment of immunotherapy-associated pruritus and prurigo nodularis refractory to dupilumab with nemolizumab. [PDF]
JAAD Case RepLuo AJ +3 more
europepmc +1 more source
Nemolizumab-induced psoriasiform dermatitis
JAAD Case ReportsAbsil, Gilles +4 more
openaire +2 more sources
Nemolizumab is associated with improved sleep duration and fewer nocturnal awakenings in patients with prurigo nodularis. [PDF]
JAAD IntMima Y, Yamamoto M, Iozumi K.
europepmc +1 more source